enters susceptible liver cells — known as hepatocytes — and begins replicating. Inside the hepatocytes, HBV produces a surplus of viral antigens, including hepatitis B e antigen (HBeAg ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy, SCG101. The therapy ...

HBV: Hepatitis B virus; TCR: T-cell receptor. Patients with chronic hepatitis B present a profound defect of hepatitis B virus (HBV)-specific T-cell immunity. Antiviral treatment in chronic ...

2 SCG101 is designed to target a specific HBV peptide presented on infected cells, as well as hepatocytes with HBV DNA integration. By triggering both cytolytic and non-cytolytic mechanisms ...